Get the Stockscreener App
2.70
1.12%
0.03
Adverum Biotechnologies Inc stock is traded at $2.70, with a volume of 61,989.
It is up +1.12% in the last 24 hours and up +4.65% over the past month.
Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.
See More
Previous Close:
$2.67
Open:
$2.69
24h Volume:
61,989
Relative Volume:
0.17
Market Cap:
$56.40M
Revenue:
-
Net Income/Loss:
$-94.11M
P/E Ratio:
-0.4493
EPS:
-6.01
Net Cash Flow:
$-86.06M
1W Performance:
-2.53%
1M Performance:
+4.65%
6M Performance:
-39.87%
1Y Performance:
-66.63%
1-Day Range:
$2.605
$2.75
1-Week Range:
$2.605
$2.89
52-Week Range:
$1.78
$8.58
Adverum Biotechnologies Inc Stock (ADVM) Company Profile
Name
Adverum Biotechnologies Inc
Sector
Industry
Phone
(650) 649-1004
Address
100 CARDINAL WAY, REDWOOD CITY, CA
Compare ADVM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ADVM
Adverum Biotechnologies Inc
|
2.70 | 55.78M | 0 | -94.11M | -86.06M | -6.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Adverum Biotechnologies Inc Stock (ADVM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-25-24 | Initiated | Oppenheimer | Outperform |
| Apr-30-24 | Initiated | H.C. Wainwright | Buy |
| Jul-07-22 | Upgrade | Truist | Hold → Buy |
| Jul-23-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| May-03-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Apr-29-21 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Apr-29-21 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Apr-29-21 | Downgrade | Truist | Buy → Hold |
| Dec-16-20 | Initiated | UBS | Neutral |
| Nov-12-20 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jun-26-20 | Downgrade | Raymond James | Mkt Perform → Underperform |
| May-13-20 | Initiated | RBC Capital Mkts | Outperform |
| May-05-20 | Upgrade | SunTrust | Hold → Buy |
| Apr-28-20 | Initiated | Goldman | Buy |
| Mar-16-20 | Initiated | SVB Leerink | Outperform |
| Feb-10-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Feb-10-20 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Oct-15-19 | Reiterated | Chardan Capital Markets | Neutral |
| Sep-13-19 | Reiterated | Chardan Capital Markets | Neutral |
| Jun-14-19 | Resumed | Raymond James | Mkt Perform |
| Nov-02-18 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-02-18 | Downgrade | SunTrust | Buy → Hold |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-30-18 | Initiated | SunTrust | Buy |
| Feb-15-18 | Resumed | Piper Jaffray | Overweight |
| Oct-12-17 | Initiated | Raymond James | Outperform |
View All
Adverum Biotechnologies Inc Stock (ADVM) Latest News
Is Adverum Biotechnologies Inc. stock a growth or value playBreakout portfolio performance - jammulinksnews.com
Adverum Biotechnologies Inc. Stock Analysis and ForecastUnrivaled growth potential - Autocar Professional
What analysts say about Adverum Biotechnologies Inc. stockTurbocharged investment results - Autocar Professional
Is Adverum Biotechnologies Inc. a good long term investmentHigh-octane financial growth - Autocar Professional
What drives Adverum Biotechnologies Inc. stock priceOutstanding stock performance - jammulinksnews.com
Presenting on Emerging Growth Conference 84 Day 2 on July 17; Register to live stream - GlobeNewswire Inc.
How Adverum Biotechnologies Inc. stock performs during market volatilityFree Access to Investment Community - Newser
what makes adverum biotechnologies inc. stock price move sharplyDaily Volume Leaders - Newser
What makes Adverum Biotechnologies Inc. stock price move sharplyFree Access to Community - Newser
Why Adverum Biotechnologies Inc. stock attracts strong analyst attentionProven High Yield Signals - Newser
Adverum Biotechnologies Up 22%, Insiders Still Down After US$526.8k Purchase - simplywall.st
Reversal Of Fortune For Adverum Biotechnologies Insiders Who Made A US$526.8k Purchase - Yahoo Finance
Adverum Biotechnologies, Inc.(NasdaqCM: ADVM) dropped from Russell 3000 Index - MarketScreener
Adverum Biotechnologies shareholders approve stock option repricing - Investing.com
Adverum Biotechnologies shareholders approve stock option repricing By Investing.com - Investing.com India
Adverum Biotechnologies’ SWOT analysis: gene therapy stock faces pivotal year - Investing.com Nigeria
Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Adverum Biotechnologies (NASDAQ:ADVM) versus Metagenomi (NASDAQ:MGX) Head-To-Head Analysis - Defense World
Adverum Awards 14,610 Shares in Stock Options and RSUs to Key New Hires - Stock Titan
Adverum Biotechnologies Reports Q1 2025 Financial Results - TipRanks
Adverum Biotechnologies (ADVM) Sees Price Target Adjustment by RBC Capital | ADVM Stock News - GuruFocus
Adverum Biotechnologies (ADVM) Receives Continued Buy Rating from Chardan Capital | ADVM Stock News - GuruFocus
Adverum Biotechnologies (ADVM) Price Target Reduced by RBC Capit - GuruFocus
Adverum Biotechnologies (ADVM) Rating Reiterated at 'Buy' by HC Wainwright | ADVM Stock News - GuruFocus
RBC Cuts Price Target on Adverum Biotechnologies to $4 From $5, Keeps Sector Perform, Speculative Risk - marketscreener.com
Adverum Biotechnologies: Q1 Earnings Snapshot - CT Insider
Adverum Biotechnologies Inc Stock (ADVM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Adverum Biotechnologies Inc Stock (ADVM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Seyedkazemi Setareh | CHIEF DEVELOPMENT OFFICER |
May 15 '25 |
Sale |
2.00 |
924 |
1,848 |
13,768 |
| Fischer Laurent | CEO, PRESIDENT AND DIRECTOR |
May 15 '25 |
Sale |
2.00 |
9,126 |
18,252 |
87,488 |
| Leonard Braden Michael | 10% Owner |
Mar 26 '25 |
Buy |
5.04 |
20,407 |
102,841 |
125,207 |
| Leonard Braden Michael | 10% Owner |
Mar 27 '25 |
Buy |
5.19 |
16,593 |
86,089 |
141,800 |
| Leonard Braden Michael | 10% Owner |
Apr 22 '25 |
Buy |
3.00 |
300,000 |
900,000 |
3,057,526 |
| Leonard Braden Michael | 10% Owner |
Apr 23 '25 |
Buy |
2.98 |
50,000 |
148,950 |
191,800 |
| Leonard Braden Michael | 10% Owner |
Mar 31 '25 |
Buy |
4.38 |
19,566 |
85,668 |
2,742,317 |
| Leonard Braden Michael | 10% Owner |
Apr 02 '25 |
Buy |
4.04 |
15,209 |
61,408 |
2,757,526 |
| Leonard Braden Michael | 10% Owner |
Mar 26 '25 |
Buy |
5.04 |
20,407 |
102,841 |
125,207 |
| Leonard Braden Michael | 10% Owner |
Mar 18 '25 |
Buy |
4.69 |
62,341 |
292,418 |
2,667,161 |
0.97%
0.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):